What You Need to Know About Clinical Endocannabinoid Deficiency Syndrome
by Dionne Dyches
You’re probably aware that cannabinoids in hemp (such as the well-known CBD, THC, CBN, CBG, CBC and others) interact with the endocannabinoid system (ECS), an intricate cell-signaling system involving endocannabinoids, receptors (such as CB1 and CB2) and enzymes including fatty acid amide hydrolase and monoacylglycerol acid lipase. The ECS which helps our bodies maintain homeostasis and plays a critical role in an array of bodily functions ranging from sleep and appetite to reproduction and fertility. The broad scope of its effects is largely due to the fact that the ECS is present in every major bodily system. And while our bodies produce endogenous cannabinoids (i.e., endocannabinoids) of their own, such as anandamide and 2-arachidonoylglycerol, recent research suggests that a deficiency in them may result in a range of conditions that can adversely impact our health and well-being. Read on to know what impact clinical endocannabinoid deficiency (CECD) can have on your body, what it means for your health and what you can do about it.
What Is Clinical Endocannabinoid Deficiency Syndrome?
CECD was first introduced into scientific discourse by Ethan Russo M.D., Director of Research and Development of the International Cannabis and Cannabinoids Institute in 2008. In the fifteen years that elapsed between his original paper discussing the issue in 2001 and his follow-up in 2016, Clinical Endocannabinoid Deficiency Reconsidered, he amassed ten years’ worth of compelling research that cogently articulated wide-reaching role of endocannabinoids and the ECS in the body. In particular, the study underlined the possibility that a deficiency of endocannabinoids or dysfunction in the ECS as a whole could link to conditions such irritable bowel syndrome, migraines and even fibromyalgia.
Since the discovery in 1988 that cannabinoid receptors were the most proliferous type of receptor in the brain, and research four years later, in 1992, of endocannabinoids, scientists have continued to rigorously study not only the ECS but emerging hypotheses, including CECD, to gain a better understanding of its complex impact on the body. The truth is that new research is constantly shedding light on topics related to the ECS, and the most exciting developments and research is yet to come.
Effects of Clinical Endocannabinoid Deficiency Syndrome
Russo’s 2016 study indicates that CECD may lower pain thresholds and disrupt mood, sleep and digestion. Research in the journal Antioxidants exploring the modulation of oxidative stress by endocannabinoids suggests that the major endogenous cannabinoids anandamide and 2-arachidonoylglycerol “are able to modulate the activity of several antioxidant enzymes through targeting” CB1 and CB2 receptors as well as additional ones. Disruptions in the ECS may consequently result in a proliferation of free radicals in the body that can damage DNA, cells and proteins.
Combatting Clinical Endocannabinoid Deficiency Syndrome
For individuals who are experiencing health problems like chronic migraine headaches and joint pain, increasing cannabinoid levels in the body by consuming pharmaceutical-grade full spectrum CBD products such as Curatio CBD — which not only contains CBD but many other powerful medicinal cannabinoids, terpenes and triglycerides that synergistically work together to produce enhanced efficacy. They also use sonification technology to produce highly bioavailable nano-particles of their active ingredient to greatly increase absorption of the medicine. Curatio’s potent full spectrum products and nanoscale delivery system can support the ECS and help reduce symptoms.
More research is needed to delve into the link between clinical endocannabinoid deficiency and traditionally treatment-resistant illnesses. Yet from what is currently known, conditions like migraine, fibromyalgia and digestive disorders and other common functional disorders suggest that CECD might be at play. The good news is that studies also show that these conditions can be “suitably treated with cannabinoid medicines.” As new research emerges on the nature of cannabinoids and the ECS as well as CECD, new treatment options will emerge and might offer a new path to alleviate chronic conditions.
Dionne Dyches, MS, is a communications professional and writer specializing in the healthcare, hospital and pharmaceuticals industry. Her niche includes internal communications, crisis communications, corporate communications, market research, management and business development.